Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

PURPOSE: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil. METHODS: A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours. The results were compared with the literature and graded according to the level of evidence. RESULTS: Adjuvant treatments benefit patients with a high risk of recurrence after surgery, and the agents used are pembrolizumab and sunitinib, with a preference for pembrolizumab. Neoadjuvant treatment is exceptional, even in initially unresectable cases. First-line treatment is mainly based on tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); the choice of treatment is based on the International Metastatic Database Consortium (IMCD) risk score. Patients at favourable risk receive ICIs in combination with TKIs. Patients classified as intermediate or poor risk receive ICIs, without preference for ICI + ICIs or ICI + TKIs. Data on nonclear cell renal cancer treatment are limited. Active surveillance has a place in treating favourable-risk patients. Either denosumab or zoledronic acid can be used for treating metastatic bone disease. CONCLUSION: Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.

Rompendo os silêncios sobre o perfil do lazer da população negra no Brasil / Breaking the silences about leisure profile of black population in Brazil

A ausência de estudos sobre o lazer e a negritude é a situação que nos chamou a atenção por reforçar, no âmbito da academia, o racismo que invisibiliza produções científicas sobre essa temática. Essa ponderação denuncia a existência do epistemicídio que reforça o apagamento cultural da negritude e reafirma a construção de uma única história em que a branquitude se coloca como centro. Dessa maneira, o objetivo desse estudo é analisar a vivência do lazer de negros e negras a partir dos dados coletados na pesquisa 'Lazer no Brasil'. A coleta de dados dessa pesquisa foi realizada através de entrevistas individuais, por levantamento amostral, utilizando um questionário estruturado com perguntas abertas e fechadas. O tamanho da amostra foi de 2.400 entrevistas no Brasil. Percebemos a necessidade de produção de pesquisas sobre o lazer da população negra, sobretudo, estudos que deem conta de questionar os saberes hegemônicos circulantes, constituídos como história única. Ainda que as pessoas possam construir desejos semelhantes sobre o lazer, as vivências e as barreiras impostas às pessoas negras, sobretudo às mulheres negras, constituem particularidades que precisam ser tensionadas.

The lack of studies on leisure and blackness is the situation that attracted our attention because it reinforces, within the academy, the racism that makes scientific productions on this subject invisible. This consideration denounces the existence of the epistemicide that reinforces the cultural erasure of blackness and reaffirms the construction of a single story in which whiteness is at the center. Thus, the aim of this study is to analyze the leisure experience of black men and women from the data collected in the 'Leisure in Brazil' survey. Data collection for this study was carried out by means of individual interviews, through a sample survey, using a structured questionnaire with open and closed-ended questions. The sample size was 2,400 interviews in Brazil. We realized the need to produce studies about the leisure of the black population, above all, studies that can interrogate the circulating hegemonic knowledge, constituted as a single story. Even though people can create similar desires about leisure, the experiences and barriers imposed on black people, especially black women, constitute features that need to be discussed.

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program.

BACKGROUND: Erdafitinib is the first targeted therapy approved for the treatment of patients with metastatic urothelial carcinoma (mUC). Approval was based on a phase II single-arm trial that demonstrated significant activity of erdafitinib in patients with tumors harboring FGFR2/3 alterations. In Brazil, an Expanded Access Program (EAP) provided patients with early access to erdafitinib prior to market authorization. The current report describes characteristics and outcomes of patients with mUC on erdafitinib therapy. METHODS: Patients with mUC that failed first- and second-line systemic therapies were screened for FGFR2/3 alterations in primary or metastatic tumor tissues. Patients with FGFR2/3 alterations were selected to receive erdafitinib at the standard dosing schedule and were followed prospectively to evaluate the efficacy and safety outcomes. RESULTS: From 19 April 2019, through 13 March 2020, 47 patients with mUC from 10 Brazilian centers were tested for FGFR2/3 alterations. Alterations in FGFR2/3 were found in 12 patients (25.5%) and all of them were eligible for the EAP. Four patients (33%) had partial response, while two patients (17%) had stable disease. Progressive disease, the best response, was observed in five patients (42%). At a median follow-up of 16.2 months, the median time to treatment failure (TTF) was 2.8 months. When considering only patients with objective response, the median TTF was 5.3 months. Adverse events (AEs) were reported for any grade and grade 3 or higher in 10 patients (83%) and 5 patients (42%), respectively. The most common AE was hyperphosphatemia. CONCLUSION: This first real-world evidence report of heavily treated patients with mUC confirms the efficacy and safety of erdafitinib in a disease setting with a lack of treatment options.

Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

PURPOSE: To present a summary of the recommendations for the treatment and follow-up for metastatic castration-resistant prostate cancer (mCRPC) as acquired through a questionnaire administered to 99 physicians working in the field of prostate cancer in developing countries who attended the Prostate Cancer Consensus Conference for Developing Countries. METHODS: A total of 106 questions out of more than 300 questions addressed the use of imaging in staging mCRPC, treatment recommendations across availability and response to prior drug treatments, appropriate drug treatments, and follow-up, and those same scenarios when limited resources needed to be considered. Responses were compiled and the percentages were presented by clinicians to support each response. Most questions had five to seven relevant options for response including abstain and/or unqualified to answer, or in the case of yes or no questions, the option to abstain was offered. RESULTS: Most of the recommendations from this panel were in line with prior consensus, including the preference of a new antiandrogen for first-line therapy of mCRPC. Important aspects highlighted in the scenario of limited resources included the option of docetaxel as treatment preference as first-line treatment in several scenarios, docetaxel retreatment, consideration for reduced doses of abiraterone, and alternative schedules of an osteoclast-targeted therapy. CONCLUSION: There was wide-ranging consensus in the treatment for men with mCRPC in both optimal and limited resource settings.

Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.

PURPOSE: To present a summary of the recommendations for the treatment and follow-up for the biochemical recurrence of castration-resistant prostate cancer (PCa) as acquired through a questionnaire administered at the Prostate Cancer Consensus Conference for Developing Countries. METHODS: A total of 27 questions were identified as relating to this topic. Responses from the clinician were tallied and are presented in percentage format. Topics included the use of imaging in staging, treatment recommendations across different patient scenarios of life expectancy and prostate-specific antigen (PSA) doubling time, and follow-up for nonmetastatic castration-resistant PCa. RESULTS: A consensus agreed that in optimal conditions, positron emission tomography-computed tomography with prostate-specific membrane antigen would be used although in limited resource situations the combined use of CT of the abdomen and pelvic (or pelvic MRI), a bone scan, and a CT of the thorax or chest x-ray was recommended. In cases when PSA levels double in < 10 months, more than 90% of clinicians agreed on the use of apalutamide or enzalutamide, regardless of life expectancy. With a doubling time of more than 10 months, > 54% of experts recommended no treatment independent of life expectancy. More than half of the experts, regardless of resources, recommended follow-up with a physical examination and PSA levels every 3-6 months and imaging only in the case of symptoms. CONCLUSION: The voting results and recommendations presented in this document can be used by physicians to support management for biochemical recurrence of castration-resistant PCa in areas of limited resources. Individual clinical decision making should be supported by available data.

Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery.

BACKGROUND: Renal cell cancer (RCC) is one of the 10 most common cancers in the world, and its incidence is increasing, whereas mortality is declining only in developed countries. Therefore, two collaborative groups, The Latin American Oncology Cooperative Group-Genitourinary Section (LACOG-GU) and the Latin American Renal Cancer Group (LARCG), held a consensus meeting to develop this guideline. METHODS: Issues (134) related to the treatment of RCC were previously formulated by a panel of experts. The voting panel comprised 26 specialists (urologists and medical oncologists) from the LACOG-GU/LARCG. A consensus was reached if 75% agreement was achieved. If there was less concordance, a new discussion was undertaken, and a consensus was determined by the most votes after a second voting session. RESULTS: The expert meeting provided recommendations that were in line with the global literature; 75.0% of the recommendations made by the panel of experts were evidence-based level A, 22.5% of the recommendations were level B, and 2.5% of the recommendations were level D. CONCLUSIONS: This review suggests recommendations for the surgical treatment of RCC according to the LACOG-GU/LARCG experts.

Custo de tratamento do câncer de próstata resistente à castração por meio da aplicação da técnica Delphi no Sistema de Saúde Suplementar brasileiro / Cost of treating castration-resistant prostate cancer by applying the Delphi method to the Brazilian Private Healthcare System

Objetivo: Estimar os custos do tratamento de pacientes com câncer de próstata não metastático resistente à castração (nmCRPC) e metastático resistente à castração (mCRPC) no Sistema de Saúde Suplementar brasileiro. Métodos: Foi realizada uma busca na literatura para avaliar os dados já disponíveis do custo do tratamento do câncer de próstata no Brasil. Como os dados são escassos, optou-se por utilizar a técnica Delphi com seis médicos oncologistas para levantamento do uso dos recursos. O painel Delphi contou com três etapas, sendo duas on-line e uma presencial, abordando recursos, frequência e porcentagem de uso de exames de imagem e laboratoriais, e dados hospitalares (consultas, pronto-socorro, internações ­ clínica, cirúrgica e em unidade de terapia intensiva). Também foram solicitados dados de padrões de tratamento do câncer de próstata. Por fim, dados do manejo das metástases foram requeridos. Por meio das informações coletadas, foi desenvolvido o microcusteio do câncer de próstata resistente à castração na perspectiva do Sistema de Saúde Suplementar. Resultados: O custo total de tratamento da jornada do paciente com câncer de próstata resistente à castração foi igual a 480.497,25 BRL, e o tratamento unicamente da doença não metastática foi de 189.832,79 BRL e o da doença metastática, de 290.664,46 BRL. Conclusão: Os custos do tratamento de câncer de próstata metastático são substancialmente superiores aos custos do tratamento do paciente não metastático resistente à castração de alto risco, o que parece justificar economicamente o uso de medidas que previnam ou adiem o surgimento de metástases.

Objective: To estimate the treatment costs for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) within the Brazilian private healthcare system. Methods: A literature search was performed to obtain currently available data on prostate cancer treatment costs in Brazil. As national data are scarce, a Delphi method with a specialist board was chosen with six oncologists for resource estimations. The Delphi panel had three steps: two online and one in-person, addressing what resources, frequencies, and percentages of use of imaging and laboratory exams, hospital data (including medical appointments, emergency room, hospitalizations - clinical, surgical and Intensive Care Unit). Data on prostate cancer treatment patterns were also requested. Finally, metastasis management data was required. Using the collected data, we developed a micro-costing model of castration-resistant prostate cancer in Brazil. Results: The total cost for the entire castration-resistant prostate cancer patient journey was 480.497,25 BRL, with the non-metastatic disease alone costing 189.832,79 BRL and the metastatic disease costing 290.664,46 BRL. Conclusion: The costs of treating metastatic prostate cancer are substantially higher than the treatment of high-risk castration-resistant non-metastatic patients, which seems to economically justify the use of measures that prevent or postpone metastasis.

Social support and common mental disorder among medical students.

INTRODUCTION: Different kinds of psychological distress have been identified for students in the health field, especially in the medical school. OBJECTIVE: To estimate the prevalence of mental suffering among medical students in the Southeastern Brazil and asses its association with social support. METHODS: It is a cross-sectional study. Structured questionnaires were applied for students from the 1st up to the 6th years of the medical school of Universidade Estadual Paulista "Júlio de Mesquita Filho", assessing demographic variables related to aspects of graduation and adaptation to the city. Psychological suffering was defined as a common mental disorder (CMD) assessed by the Self Reporting Questionnaire (SRQ-20). Social support was assessed by the social support scale of the Medical Outcomes Study (MOS). The association between the outcome and explanatory variables was assessed by the χ2 test and Logistic Regression, for the multivariate analyses, using p < 0.05. RESULTS: The response rate was of 80.7%, with no differences between sample and the population regarding gender (p = 0.78). The average age was 22 years old (standard deviation - SD = 2.2), mainly women (58.2%) and students who were living with friends (62%). The prevalence of CMD was 44.9% (95%CI 40.2 - 49.6). After the multivariate analyses, the explanatory variables that were associated with CMD were: feeling rejected in the past year (p < 0.001), thinking about leaving medical school (p < 0.001) and "interaction" in the MOS scale (p = 0.002). CONCLUSIONS: The prevalence of CMD among medical students was high and insufficient social support was an important risk factor. Our findings suggest that interventions to improve social interaction among those students could be beneficial, decreasing the prevalence of CMD in this group.

Social support and common mental disorder among medical students / Apoio social e transtorno mental comum entre estudantes de Medicina

INTRODUCTION: Different kinds of psychological distress have been identified for students in the health field, especially in the medical school. OBJECTIVE: To estimate the prevalence of mental suffering among medical students in the Southeastern Brazil and asses its association with social support. METHODS: It is a cross-sectional study. Structured questionnaires were applied for students from the 1st up to the 6th years of the medical school of Universidade Estadual Paulista "Júlio de Mesquita Filho", assessing demographic variables related to aspects of graduation and adaptation to the city. Psychological suffering was defined as a common mental disorder (CMD) assessed by the Self Reporting Questionnaire (SRQ-20). Social support was assessed by the social support scale of the Medical Outcomes Study (MOS). The association between the outcome and explanatory variables was assessed by the χ2 test and Logistic Regression, for the multivariate analyses, using p < 0.05. RESULTS: The response rate was of 80.7%, with no differences between sample and the population regarding gender (p = 0.78). The average age was 22 years old (standard deviation - SD = 2.2), mainly women (58.2%) and students who were living with friends (62%). The prevalence of CMD was 44.9% (95%CI 40.2 - 49.6). After the multivariate analyses, the explanatory variables that were associated with CMD were: feeling rejected in the past year (p < 0.001), thinking about leaving medical school (p < 0.001) and "interaction" in the MOS scale (p = 0.002). CONCLUSIONS: The prevalence of CMD among medical students was high and insufficient social support was an important risk factor. Our findings suggest that interventions to improve social interaction among those students could be beneficial, decreasing the prevalence of CMD in this group. .

INTRODUÇÃO: Diferentes formas de sofrimento psíquico têm sido identificadas em estudantes da área da saúde, em especial no curso de Medicina. OBJETIVO: Estimar a prevalência de sofrimento psíquico entre estudantes de Medicina em uma faculdade no Sudeste do Brasil e avaliar sua associação com apoio social. MÉTODO: Trata-se de um estudo transversal. Foram aplicados questionários para alunos do 1º ao 6º ano do curso de Medicina da Universidade Estadual Paulista "Júlio de Mesquita Filho", investigando-se características demográficas relacionadas ao curso e à adaptação à cidade. Sofrimento psíquico foi investigado na forma de Transtorno Mental Comum (TMC), avaliado por meio do Self-Reporting Questionnaire (SRQ-20). Apoio social foi avaliado com a Escala de Apoio Social (EAS). As associações entre o desfecho e as variáveis explanatórias foram analisadas por meio do teste do χ2 e, na análise multivariada, por meio da Regressão Logística, com p < 0,05. RESULTADOS: A taxa de resposta foi de 80,7%, não havendo diferença estatística entre a mostra e a população-alvo no que diz respeito ao gênero (p = 0,78). A média de idade foi de 22 anos (desvio padrão - DP = 2,2) com predomínio de mulheres (58,2%) e estudantes que vivem com amigos (62%). A prevalência de TMC foi de 44,9% (IC95% 40,2 - 49,6). Após a análise multivariada, mantiveram-se associados a TMC: sentir-se rejeitado no último ano (p < 0,001), ter pensado ou pensar em abandonar o curso (p < 0,001) e "interação", avaliada pela EAS (p = 0,002). CONCLUSÕES: A prevalência de TMC entre estudantes de Medicina mostrou-se elevada, identificando-se o apoio social insuficiente como fator de risco. Esses achados sugerem que intervenções ...

Formando grupos no internato: critérios de escolha, satisfação e sofrimento psíquico / Formation of groups during internship: selection criteria, satisfaction, and psychological distress

OBJETIVO: Descrever os critérios para formação de grupos no internato e a avaliação que os alunos fazem do relacionamento grupal, analisando as variáveis associadas. MÉTODO: Trata-se de um estudo transversal, que utilizou questionário autopreenchido, com perguntas sobre dados sociodemográficos, autoavaliação do desempenho escolar, critérios para formação e satisfação com grupo de internato. Sofrimento psíquico foi avaliado a partir do Self Report Questionnaire. Utilizou-se o teste do qui-quadrado e regressão logística para análise multivariada. RESULTADOS:A taxa de resposta no internato foi de mais de 90 por cento. A maioria dos alunos utilizou critérios ligados à rede social (82,6 por cento) e predominaram sujeitos satisfeitos com seu grupo (81,2 por cento). Após análise multivariada, apenas autoavaliação do desempenho escolar "boa ou ótima" e critérios de escolha relacionados à rede de apoio se mantiveram associados à satisfação com o grupo. CONCLUSÕES: Apesar de ser um estágio da formação profissional, os alunos se escolheram por questões ligadas à rede social. Sendo uma profissão na qual o trabalho em equipe é inerente, deveriam ser criadas estratégias durante o curso médico para elaborar as dificuldades de relacionamento grupal entre alunos de Medicina.

OBJECTIVE: To describe the criteria used in forming groups during medical internship and the students' evaluation of group relations, including analysis of the associated variables. METHOD: Cross-sectional study using self-completed questionnaires consisting of questions on socio-demographic data, self-rating of academic performance, selection criteria, and satisfaction with the group of interns. Psychological distress was assessed based on the Self-Report Questionnaire. The chi-square test and logistic regression were used for multivariate analysis. RESULTS: Response rate among interns was over 90 percent. The majority of the students used criteria related to the social network (82.6 percent) and reported satisfaction with their groups (81.2 percent). After multivariate analysis, only "good or excellent" self-evaluated academic performance and selection criteria related to the support network remained associated with group satisfaction. CONCLUSIONS: Although internship is a stage of professional training, in this study students chose each other based on reasons related to social networking. Given that teamwork is inherent to the medical profession, strategies should be created during the course to help students overcome their difficulties with group relations in order to reduce stress and improve training.